TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26718373
Drug: Compound topical
Normalized name: benzoin compound TOPICAL TINCTURE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound topical anesthetic (CTA)
Study: 26718373
Drug: Needle injection
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle injection of local anesthetic
Study: 22678100
Drug: Antiaggregation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiaggregation therapy
Study: 18387222
Drug: Levocetirizine (LCTZ),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocetirizine (LCTZ), 5 mg
Study: 18387222
Drug: Montelukast (MLKT),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (MLKT), 10 mg
Study: 10077045
Drug: Erythromycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (1 g i.v. per day for 10 days)
Study: 10077045
Drug: Erythromycin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (2 g i.v. per day for 10 days)
Study: 10077045
Drug: Erythromycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (1 g oral per day for 1.5 to 8 months)
Study: 10077045
Drug: Erythromycin (discontinuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (discontinuation after 1.5 to 8 months)
Study: 7561633
Drug: GHRH (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH (100 micrograms in 1 ml saline) injected as an i.v. bolus
Study: 7561633
Drug: Hexarelin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexarelin (100 micrograms in 1 ml saline) injected as an i.v. bolus
Study: 7561633
Drug: Hexarelin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexarelin (100 micrograms in 1 ml saline) plus GHRH (100 micrograms in 1 ml saline) injected as an i.v. bolus
Study: 2185569
Drug: Alpha-tocopherol acetate
Normalized name: alpha-Tocopherol acetate
DrugBank: alpha-Tocopherol acetate (DB14003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alpha-tocopherol acetate (600 mg)
Study: 2185569
Drug: Placebo (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (600 mg)
Study: 28177133
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + dietary supplementation of low-dose omega-3 PUFAs (6.25 mg eicosapentaenoic acid and 19.19 mg docosahexaenoic acid)
Study: 28177133
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + dietary supplementation of low-dose omega-3 PUFAs
Study: 25148566
Drug: Take Charge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take Charge of Your Life drug prevention program
Study: 19197383
Drug: 7.5 microg
Normalized name: Levonorgestrel 37.5 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 microg dose of MF59-adjuvanted H5N1 vaccine
Study: 19197383
Drug: 15 microg
Normalized name: Tafluprost 15 microgram/mL eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 microg dose of MF59-adjuvanted H5N1 vaccine
Study: 19197383
Drug: Both formulations
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both formulations of MF59-adjuvanted H5N1 vaccine
Study: 12751274
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg M100240 via short intravenous infusion
Study: 12751274
Drug: Oral immediate-release
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immediate-release tablet administration
Study: 12751274
Drug: Oral Enterion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Enterion capsule delivery to the proximal small bowel
Study: 12751274
Drug: Oral immediate-release
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immediate-release formulation of M100240
Study: 11083625
Drug: Ciprofloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (400 mg t.i.d. for at least 72 h followed by 750 mg b.i.d. orally)
Study: 11083625
Drug: Ceftazidime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (2 g t.i.d. intravenously) plus Amikacin (500 mg b.i.d. intravenously)
Study: 7594063
Drug: Propionyl-L-carnitine
Normalized name: GLYCINE PROPIONYL-L-CARNITINE
DrugBank: Levocarnitine propionate (DB15980)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propionyl-L-carnitine
Study: 2854609
Drug: Sublingual prazepam
Normalized name: prazepam
DrugBank: Prazepam (DB01588)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual prazepam 20 mg
Study: 2854609
Drug: Oral prazepam
Normalized name: prazepam
DrugBank: Prazepam (DB01588)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prazepam 20 mg
Study: 31330502
Drug: Suspension Training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension Training (ST)
Study: 20398849
Drug: Postoperative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative therapy with concurrent chemoradiotherapy plus fluoropyrimidine-based chemotherapy
Study: 18636998
Drug: Usual addiction
Normalized name: DRUGS USED IN ADDICTIVE DISORDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual addiction treatment (control group)
Study: 10660730
Drug: Chemotherapy based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy based on evidence-based medicine (EBM)
Study: 9138996
Drug: Measurements (CC,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measurements (CC, CA, HA, (CA‐HA) x 100/CA)
Study: 1827010
Drug: Isradipine 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine 1.25 to 2.5 mg twice daily
Study: 6291439
Drug: Conjugated estrogen
Normalized name: Conjugated estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated estrogen therapy (0.6 mg/d)
Study: 6291439
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and low-dose treatment groups
Study: 20340011
Drug: Citalopram (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20-40 mg/d)
Study: 19056706
Drug: Vitamin/nutriceutical formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin/nutriceutical formulation (folate, vitamin B12, alpha‐tocopherol, S‐adenosyl methionine, N‐acetyl cysteine, and acetyl‐L‐carnitine)
Study: 19056706
Drug: Vitamin/nutriceutical formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin/nutriceutical formulation
Study: 15026402
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline (HTS) - 250 mL of 7.5% saline
Study: 15026402
Drug: Control -
Normalized name: HISTAMINE 6 mg in 1 mL PERCUTANEOUS INJECTION [Positive Skin Test Control - Histamine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control - 250 mL of Ringer's lactate solution
Study: 9664090
Drug: Montelukast 10
Normalized name: montelukast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 10 mg once daily at bedtime for 12 weeks
Study: 7927227
Drug: Emergency medical
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emergency medical therapy (intravenous vasopressin and esophageal balloon tamponade) followed by elective portacaval shunt
Study: 9184881
Drug: Emergency medical
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emergency medical therapy
Study: 7927227
Drug: Emergency medical
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emergency medical therapy followed by elective shunt
Study: 3056505
Drug: 1‐mg gemeprost
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1‐mg gemeprost (Cervagem) pessary
Study: 24886272
Drug: Spironolactone 25
Normalized name: spironolactone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 25 mg once daily for 40 weeks
Study: 31694122
Drug: Exercise rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise rehabilitation training and routine therapy
Study: 31694122
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment only (physical therapy and NSAIDs)
Study: 9108457
Drug: GM‐CSF gene‐transduced
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM‐CSF gene‐transduced vaccines
Study: 9108457
Drug: Nontransduced vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nontransduced vaccines
Study: 9108457
Drug: GM‐CSF gene‐transduced
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM‐CSF gene‐transduced vaccine
Study: 2860136
Drug: Propranolol, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol, 20 to 30 mg/day
Study: 2860136
Drug: Lorazepam, 2
Normalized name: Lorazepam, 2 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam, 2 mg/day
Study: 23992231
Drug: 3125 U/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3125 U/mL heparin saline (HS)
Study: 20808854
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid (VPA) and L-carnitine for 6 months
Study: 20808854
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid (VPA) and L-carnitine for 12 months (post-hoc analysis)
Study: 20808854
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (VPA and L-carnitine)
Study: 20808854
Drug: Age factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age factor in treatment
Study: 7600115
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (2 IU.m‐2.d‐1)
Study: 7600115
Drug: Insulin-like growth
Normalized name: Insulin-like growth factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-like growth factor-I (80 micrograms.kg‐1.d‐1)
Study: 2145790
Drug: Inhaled albuterol
Normalized name: albuterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled albuterol (A) alone
Study: 2145790
Drug: Inhaled albuterol
Normalized name: albuterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled albuterol (A) plus ipratropium bromide (IB)
Study: 25925992
Drug: Rivaroxaban 10
Normalized name: rivaroxaban 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 10 mg plus UFH
Study: 24120550
Drug: HIV-v (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-v (250 μg or 500 μg, either alone or adjuvanted with ISA-51)
Study: 24120550
Drug: HIV-v (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-v (high adjuvanted dose)
Study: 19808134
Drug: Roxithromycin 300
Normalized name: roxithromycin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxithromycin 300 mg once daily for 3 months
Study: 19808134
Drug: Placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for 3 months
Study: 11116754
Drug: Clarithromycin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (250 mg) co-administered with tolbutamide (500 mg)
Study: 11116754
Drug: Tolbutamide (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolbutamide (500 mg) alone
Study: 8371129
Drug: Ondansetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (8 mg iv loading dose followed by 1 mg/hour continuous infusion for the treatment period)
Study: 8371129
Drug: Chlorpromazine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine (60 mg/m2/day by continuous infusion for the same period, maximum 8 days)
Study: 17196413
Drug: Theophylline treatment
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline treatment (0.2g, orally, q 12h for 1 month)
Study: 7767539
Drug: Theophylline treatment
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline treatment
Study: 10705222
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no theophylline treatment)
Study: 10333620
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cimetidine and levamisole (group B)
Study: 8600545
Drug: rhIL-3 (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIL-3 (2.5 or 5.0 microg/kg/d) administered by subcutaneous injection for either 5 or 10 days following ABMT.
Study: 8600545
Drug: rhGM-CSF (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGM-CSF (250 microg/m2/d as a 2-hour intravenous infusion) administered 24 hours after the last dose of rhIL-3.
Study: 8600545
Drug: Sequential cytokine
Normalized name: cytosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential cytokine therapy (rhIL-3 and rhGM-CSF) post-ABMT.
Study: 9008458
Drug: Verapamil 480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 480 mg
Study: 3297230
Drug: Indomethacin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (50 mg)
Study: 26309133
Drug: Full-mouth non-surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-mouth non-surgical treatment (FM-SRP)
Study: 19564319
Drug: Therapeutic allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Therapeutic allopurinol (500 mg intravenously)
Study: 16972973
Drug: Intravenous frusemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous frusemide 2 mg/kg
Study: 8329287
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg racemic ibuprofen (RAC)
Study: 8329287
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg (S)-ibuprofen (S-IBU)
Study: 25546356
Drug: Gut microbiota
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gut microbiota metabolism
Study: 19787380
Drug: Infusion set
Normalized name: INFUSION SET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion set (500-cc solution bag with gravity-driven delivery)
Study: 19787380
Drug: Infusion pump
Normalized name: Infusion Pump 50cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion pump
Study: 15937041
Drug: Transdermal secretin
Normalized name: Secretin
DrugBank: Secretin human (DB09532)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal secretin applied daily in ointment form for 4 weeks
Study: 15937041
Drug: Placebo applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo applied daily in ointment form for 4 weeks
Study: 10987150
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy (active and passive jaw movement exercises, correction of body posture, and relaxation techniques)
Study: 8988067
Drug: Watercress +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Watercress + Acetaminophen
Study: 1455306
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution subcutaneously every 8 hours
Study: 1455306
Drug: Octreotide and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide and Saline solution
Study: 26959482
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D 3 1,000 IU daily for 6 months
Study: 25149431
Drug: Modified vaccinia
Normalized name: Modified vaccinia ankara
DrugBank: Modified vaccinia ankara (DB15483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified vaccinia Ankara (MVA) vaccine administered by subcutaneous injection at Week 0 and 4
Study: 25149431
Drug: Modified vaccinia
Normalized name: Modified vaccinia ankara
DrugBank: Modified vaccinia ankara (DB15483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified vaccinia Ankara (MVA) vaccine
Study: 22240180
Drug: Intraoperative music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative music added to routine pain control measures (ibuprofen and paracervical block)
Study: 22240180
Drug: Routine pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine pain control measures only (ibuprofen and paracervical block)
Study: 20416451
Drug: Montelukast 10
Normalized name: montelukast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 10 mg oral tablets daily for one month
Study: 17687689
Drug: cetirizine 10
Normalized name: cetirizine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: cetirizine 10 mg/day
Study: 17687689
Drug: doxepine 10
Normalized name: doxepin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: doxepine 10 mg/day
Study: 17687689
Drug: hydroxyzine 25
Normalized name: hydroxyzine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydroxyzine 25 mg/day
Study: 9495433
Drug: Fentanyl (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (2 microg/kg) administered 1 min before intubation
Study: 9495433
Drug: Fentanyl (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (2 microg/kg) administered 3 min before intubation
Study: 9495433
Drug: Fentanyl (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (2 microg/kg) administered 5 min before intubation
Study: 9495433
Drug: Fentanyl (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (2 microg/kg) administered 10 min before intubation
Study: 2668060
Drug: 3 days
Normalized name: Transderm Scop 1mg/3 days Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 days treatment with amoxycillin (1.5 g/day)
Study: 2668060
Drug: 10 days
Normalized name: AlleRx 10-day Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 days therapy (750 mg amoxycillin/day)
Study: 1213890
Drug: Topical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment with estrogen in an alcoholic vehicle (0.05% dienestroldiacetate) applied daily on the scalp skin
Study: 1213890
Drug: Corresponding preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corresponding preparation without estrogen (control group)
Study: 1213890
Drug: Topical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment with estrogen
Study: 31091575
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose remifentanil (Group L)
Study: 31091575
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose remifentanil (Group H)
Study: 31091575
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose remifentanil with gradual withdrawal (Group G)
Study: 25520333
Drug: Multicomponent intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multicomponent intervention protocol (manual tooth/gum brushing plus 0.12% chlorhexidine oral rinse, twice per day, plus upright positioning during feeding)
Study: 21777835
Drug: Intercoat gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intercoat gel (polyethylene oxide-sodium carboxymethylcellulose) applied intrauterinely during hysteroscopic surgery
Study: 27999118
Drug: Oral Contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Contraceptives (OCs)
Study: 12116891
Drug: Acetaminophen 500
Normalized name: acetaminophen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 500 mg caplets and i.v. argatroban 1.5 micrograms/kg/min
Study: 12116891
Drug: Lidocaine 2
Normalized name: lidocaine 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 2 mg/kg/hr and i.v. argatroban 1.5 micrograms/kg/min
Study: 12116891
Drug: Oral digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral digoxin 0.375 mg/day and i.v. argatroban 2 micrograms/kg/min
Study: 11206232
Drug: Formoterol 24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol 24 microg twice daily
Study: 9525449
Drug: Formoterol 24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol 24 microg once daily
Study: 7712753
Drug: Selective decontamination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective decontamination of the digestive tract (parenteral cefotaxime, oral and enteral polymyxin E, amphotericin B, tobramycin)
Study: 7960687
Drug: nizatidine 300
Normalized name: nizatidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nizatidine 300 mg
Study: 363631
Drug: Mazindol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mazindol (2 mg/day)
Study: 23748458
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy at a dose of 4 J/cm²
Study: 23748458
Drug: Needling with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needling with 2% lidocaine injection
Study: 8172700
Drug: VT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: VT with medication
Study: 8172700
Drug: VT without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VT without medication
Study: 30862667
Drug: JT010 (TRPA1
Approvals — FDA: no, EMA: no, PMDA: no
Description: JT010 (TRPA1 agonist)
Study: 30862667
Drug: A-967079 (TRPA1
Approvals — FDA: no, EMA: no, PMDA: no
Description: A-967079 (TRPA1 antagonist)
Study: 25807891
Drug: Rapid Syllable
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid Syllable Transition (ReST) treatment
Study: 23943468
Drug: Continuous antiretroviral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous antiretroviral therapy (ART)
Study: 12538746
Drug: Cyclosporine treatment
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine treatment for 24 weeks
Study: 12224599
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 24 weeks
Study: 11142481
Drug: Alternating regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating regimen of bolus and continuous infusion 5-FU (200 mg/m2 continuous infusion) + weekly bolus 6-S-leucovorin (20 mg/m2)
Study: 11142481
Drug: Control arm:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control arm: biweekly cycles of MTX (200 mg/m2 on day 1) followed by bolus 5-FU (600 mg/m2 on day 2) + 6-S-leucovorin rescue
Study: 9095423
Drug: Once-daily wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily wound cleansing and dressing change
Study: 9095423
Drug: Twice-daily dressing
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily dressing changes (Control)
Study: 8242966
Drug: Subcutaneous apomorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous apomorphine (mean optimal dose of 2.7 mg)
Study: 9856921
Drug: Intravenous procainamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous procainamide
Study: 3728294
Drug: Intravenous quinidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous quinidine